Exhibit A

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION	**MDL 2724** **16-MD-2724** **HON. CYNTHIA M. RUFE**
THIS DOCUMENT RELATES TO:	
The State Attorney General Litigation	**Civil Action No. 17-3768**

DECLARATION OF DANIEL H. LEFF IN SUPPORT OF STATES' RESPONSE IN OPPOSITION TO EMCURE PHARMACEUTICALS LTD. AND SATISH MEHTA'S MOTION TO DISMISS THE PLAINTIFF STATES' CONSOLIDATED AMENDED COMPLAINT

I, Daniel H. Leff, declare under penalty of perjury as follows:

1. I am an Assistant Attorney General for the Commonwealth of Massachusetts and am one of the counsel for the Plaintiff States ("States") in this action. I make this declaration in support of States' opposition to Defendant Satish Mehta and Emcure Pharmaceuticals Ltd.'s ("Emcure") motion to dismiss States Consolidated Amended Complaint.

2. I am familiar with the documents attached to this declaration, which include publicly available documents and documents produced by Heritage Pharmaceuticals, Inc. ("Heritage") to the Connecticut Attorney General's Office during the course of Connecticut's investigation into antitrust violations in the generic pharmaceuticals industry. The documents produced by Heritage are marked with Bates numbers beginning with "HER" or "EMC."

3. Attached hereto as Attachment 1 is an excerpt of a true and correct copy of a document Bates numbered HER-CTAG-000542966-000543092.

4. Attached hereto as Attachment 2 is a true and correct copy of a corporate disclosure filed by Heritage in Heritage Pharmaceuticals Inc. v. Glazer, 3:16-cv-08483-PGS-TJB (D.N.J.).

5. Attached hereto as Attachment 3 is a true and correct copy of a document Bates numbered EMC-VT-00007977-00007982 and its transmittal email Bates numbered EMC-VT-00018527.

6. Attached hereto as Attachment 4 is a true and correct copy of a document Bates numbered EMC-SM-00003154-00003155.

7. Attached hereto as Attachment 5 is an excerpt of a true and correct copy of a document Bates numbered EMC-VT-00002249-00002284.

8. Attached hereto as Attachment 6 is a true and correct copy of a February 6, 2019 press release posted on Emcure's website.

9. Attached hereto as Attachment 7 is a true and correct copy of a document Bates numbered EMC-SM-00005865-00005868.

10. Attached hereto as Attachment 8 is a true and correct copy of a document Bates numbered EMC-SM-00005014-00005018.

11. Attached hereto as Attachment 9 is a true and correct copy of a document Bates numbered EMC-VT-00000876-00000877.

12. Attached hereto as Attachment 10 is an excerpt of a true and correct copy of a document Bates numbered HER-CTAG-000542602-000542722.

13. Attached hereto as Attachment 11 is a true and correct copy of a document Bates numbered EMC-SM-00006189-00006190.

14. Attached hereto as Attachment 12 is a true and correct copy of a document Bates numbered EMC-SM-00000221-00000222.

15. Attached hereto as Attachment 13 is a true and correct copy of a document Bates numbered EMC-SM-00006300-00006301.

16. Attached hereto as Attachment 14 is a true and correct copy of a document Bates numbered EMC-SM-00004564-00004567.

17. Attached hereto as Attachment 15 is a true and correct copy of a document Bates numbered EMC-SM-00005621-00005623.

18. Attached hereto as Attachment 16 is a true and correct copy of a document Bates numbered EMC-SM-00005956-00005963.

19. Attached hereto as Attachment 17 is a true and correct copy of a document Bates numbered EMC-VT-00000506.

20. Attached hereto as Attachment 18 is a true and correct copy of a document Bates numbered EMC-SM-00000070-00000076 and its transmittal email Bates numbered EMC-SM-00005691-00005692.

21. Attached hereto as Attachment 19 is a true and correct copy of a document Bates numbered HER-CTAG-000635133.

22. Attached hereto as Attachment 20 is a true and correct copy of a document Bates numbered EMC-SM-00000362-00000365.

23. Attached hereto as Attachment 21 is a true and correct copy of a document Bates numbered EMC-SM-00004366.

24. Attached hereto as Attachment 22 is a true and correct copy of a document Bates numbered EMC-SM-00002061-00002064.

25. Attached hereto as Attachment 23 is a true and correct copy of a document Bates numbered HER-JM-000020747-000020751.

26. Attached hereto as Attachment 24 is a true and correct copy of a document Bates numbered EMC-SM-00005042-00005044.

27. Attached hereto as Attachment 25 is a true and correct copy of a document Bates numbered EMC-VT-00012318-00012319.

28. Attached hereto as Attachment 26 is a true and correct copy of a document filed by Emcure and Heritage in *Novartis Pharm. Corp. v. Accord Healthcare Inc.*, C.A. No. 18-1043-LPS (D. Del.).

29. Attached hereto as Attachment 27 is a true and correct copy of a document Bates numbered HER-CTAG-000037848.

30. Attached hereto as Attachment 28 is a true and correct copy of a document Bates numbered EMC-VT-00016337-00016339.

31. Attached hereto as Attachment 29 is a true and correct copy of a document Bates numbered EMC-SM-00004278-00004279.

32. Attached hereto as Attachment 30 is a true and correct copy of a document Bates numbered EMC-SM-00005147-00005148.

33. Attached hereto as Attachment 31 is a true and correct copy of a document Bates numbered EMC-VT-00002312.

34. Attached hereto as Attachment 32 is a true and correct copy of a document Bates numbered EMC-VT-00014687.

35. Attached hereto as Attachment 33 is a true and correct copy of a document Bates numbered EMC-VT-00003691-00003692.

36. Attached hereto as Attachment 34 is a true and correct copy of a record of Emcure's Missouri drug distributor license.

37. Attached hereto as Attachment 35 is a true and correct copy of search results on the U.S. Food and Drug Administration Orange Book website for drugs Emcure has had approved for sale in the United States.

38. Attached hereto as Attachment 36 is a true and correct copy of a document Bates numbered EMC-SM-00001174-00001176.

39. Attached hereto as Attachment 37 is a true and correct copy of a document Bates numbered EMC-SM-00000230-00000231.

40. Attached hereto as Attachment 38 is a true and correct copy of a document Bates numbered EMC-VT-00016305.

41. Attached hereto as Attachment 39 is a true and correct copy of a document Bates numbered EMC-VT-00012611-00012612.

I declare under penalty of perjury that the forgoing is true and accurate to the best of my knowledge.

Executed on: July 26, 2019

By: 

Daniel H. Leff

Attachment 1
(filed under seal)

Attachment 2

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY

HERITAGE PHARMACEUTICALS INC., Plaintiff, v. JEFFREY A. GLAZER and JASON T. MALEK, Defendants.	CORPORATE DISCLOSURE STATEMENT

Liza M. Walsh
Marc. D. Haefner
WALSH PIZZI O'REILLY FALANGA LLP
One Riverfront Plaza
1037 Raymond Blvd., Suite 600
Newark, NJ 07102
(t) (973) 757-1100
(f) (973) 757-1090

Daniel W. Nelson (*pro hac vice forthcoming*)
William Jeremy Robison (*pro hac vice forthcoming*)
GIBSON, DUNN & CRUTCHER LLP
1050 Connecticut Ave., N.W.
Washington, D.C. 20036
(t) (202) 955-8500
(f) (202) 467-0539

Attorneys for Plaintiff Heritage Pharmaceuticals Inc.

CORPORATE DISCLOSURE STATEMENT

Pursuant to Rule 7.1(a) of the Federal Rules of Civil Procedure, Plaintiff Heritage Pharmaceuticals Inc. (a non-governmental corporate party), by and through counsel, hereby states as follows regarding affiliates:

Plaintiff Heritage Pharmaceuticals Inc. is a wholly owned subsidiary of Heritage Pharmaceuticals Holdings Inc., which is a wholly owned subsidiary of Emcure Pharmaceuticals Ltd., an Indian corporation. Plaintiff Heritage Pharmaceuticals Inc. is not a publicly traded entity, and no other parent corporation or publicly held corporation holds 10% or more of Plaintiff Heritage Pharmaceuticals Inc.'s stock.

We certify under penalty of perjury the foregoing statements are true and correct.

Dated: November 10, 2016

Respectfully submitted,

By:*/s/Liza M. Walsh*

Liza M. Walsh
Marc D. Haefner
WALSH PIZZI O'REILLY FALANGA LLP
One Riverfront Plaza
1037 Raymond Blvd., Suite 600
Newark, NJ 07102
Telephone: (973) 757-1100
Facsimile: (973) 757-1090
Email: lwalsh@walsh.law

Daniel W. Nelson (*pro hac vice forthcoming*)
William Jeremy Robison (*pro hac vice forthcoming*)
GIBSON, DUNN & CRUTCHER LLP
1050 Connecticut Ave., N.W.
Washington, D.C. 20036
Telephone: (202) 887-3687
Facsimile: (202) 530-9571
Email: dnelson@gibsondunn.com

Attorneys for Plaintiff Heritage Pharmaceuticals, Inc.

Attachment 3
(filed under seal)

Attachment 4
(filed under seal)

Attachment 5
(filed under seal)

Attachment 6

Heritage Pharma Labs Inc. Announces Acquisition of 23 FDA-Approved ANDAs

East Brunswick, NJ, February 6, 2019 – Heritage Pharma Labs Inc. (Heritage) today announced that they have acquired a portfolio of 23 abbreviated new drug applications (ANDAs), covering 17 product families, all of which have been previously approved by the U.S. Food and Drug Administration (FDA). Financial terms were not disclosed.

Of the newly acquired products, Heritage and its parent company, Emcure Pharmaceuticals Ltd. had previously manufactured most of these products under a supply agreement with a third party, and Heritage plans to launch all of these products into the U.S. market under a Heritage label with immediate availability starting in Q2 2019 through its affiliate, Heritage Pharmaceuticals Inc.

"The addition of these new products to our growing portfolio is another step forward in our efforts to strengthen our U.S. business and operations," stated William S. Marth, the Global President and CEO of the Heritage Group, Regulated Markets. Mr. Marth added that "we remain focused on delivering high-quality products to our customers and patients. Our previous experience producing the vast majority of these products will enable us to quickly resume manufacturing and begin production immediately."

About Heritage

A wholly owned subsidiary of Emcure Pharmaceuticals Limited, and strategically located in East Brunswick, New Jersey, Heritage Pharma Labs Inc. is a specialty pharmaceutical company engaged in the development, manufacturing, packaging, and sales of generic and legacy branded pharmaceutical products for the U.S. prescription drug market. Since inception, our customers have experienced the benefits of our continuous product expansion and global alliance network among the Emcure and Heritage Group family that has produced an impressive portfolio of over 150 products spanning multiple dosage forms. The Heritage Group's products cover several therapeutic categories, including but not limited to: oncology, cardiovascular, metabolic disease, anti-infective and pain management. Whether its oral solids or complex injectables, the Heritage portfolio is poised to continue to rapidly expand and deliver the Value Driven Medicine required to keep our customers competitive in the marketplace. Let our formula of high quality and consistent supply work for you as we continue to provide affordable healthcare solutions to the U.S. consumer.

###

Attachment 7
(filed under seal)

Attachment 8
(filed under seal)

Attachment 9
(filed under seal)

Attachment 10
(filed under seal)

Attachment 11
(filed under seal)

Attachment 12
(filed under seal)

Attachment 13
(filed under seal)

Attachment 14
(filed under seal)

Attachment 15
(filed under seal)

Attachment 16
(filed under seal)

Attachment 17
(filed under seal)

Attachment 18
(filed under seal)

Attachment 19
(filed under seal)

Attachment 20
(filed under seal)

Attachment 21
(filed under seal)

Attachment 22
(filed under seal)

Attachment 23
(filed under seal)

Attachment 24
(filed under seal)

Attachment 25
(filed under seal)

Attachment 26

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

NOVARTIS PHARMACEUTICALS CORPORATION Plaintiff, v. ACCORD HEALTHCARE INC., et al. Defendants.	C.A. No. 18-1043-LPS

STIPULATION AND [PROPOSED] ORDER

WHEREAS, Plaintiff Novartis Pharmaceuticals Corporation ("Novartis") owns U.S. Patent No. 5,604,229 ("the '229 patent"), directed to the active ingredient, fingolimod, in Gilenya®, the Novartis branded product indicated for patients with relapsing-remitting multiple sclerosis;

WHEREAS, Defendant Emcure Pharmaceuticals, Ltd. ("Emcure") filed Abbreviated New Drug Application No. 207927 through its U.S. subsidiary, Defendant Heritage Pharmaceuticals Inc. (together with Emcure, "Heritage"), for permission to sell generic Gilenya upon expiration of the '229 patent;

WHEREAS, the '229 patent precludes the sale of a generic version of Novartis's Gilenya brand medication until August 18, 2019;

WHEREAS, several Petitioners (but not Heritage) brought an *inter-partes* review challenging all of the claims of U.S. Patent No. 9,187,405 ("the '405 patent"), the Novartis patent that is the subject of the present action;

WHEREAS, the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office determined that Petitioners did not establish by a preponderance of the evidence the unpatentability of all of the claims of the '405 patent in a Final Written Decision issued on July 11, 2018 in IPR2017-00854 (attached as Exhibit B to the Complaint in this action);

WHEREAS, Novartis contends in this action that the '405 patent precludes the sale of generic Gilenya until 2027, which Heritage denies;

WHEREAS, Novartis seeks to expeditiously resolve its claims in this matter in view of the August 18, 2019 expiration date of the '229 patent;

WHEREAS, Novartis envisions that a motion for preliminary injunctive relief or other forms of preliminary relief may be sought to preserve the *status quo* if the present action is not resolved by August 19, 2019; and

WHEREAS, Novartis served Heritage with the Complaint in this action on July 19, 2018, and Heritage has asked for a sixty-day extension of time to respond to the Complaint, such that its response to the Complaint would be due on October 8, 2018;

IT IS HEREBY STIPULATED AND AGREED, by and between Novartis and Heritage, as follows:

1. Heritage's time to answer the Complaint shall be extended to October 8, 2018.

2. Heritage shall not file any motion under Federal Rule of Civil Procedure 12 in this action; any motion directed to process, sufficiency of process, personal jurisdiction or venue; or any other motion before answering the Complaint. For the avoidance of doubt, Heritage agrees to litigate this action in the District of Delaware and, solely for the purposes of this action, waives any challenge to venue or personal jurisdiction it may otherwise have.

3. Heritage shall not use the delay in answering the Complaint as the basis for, or in connection with, any argument in opposition to any form of temporary, preliminary or expedited relief sought by Novartis in this matter, including without limitation, a request for an expedited case schedule.

4. Regardless of having not yet answered the Complaint, Heritage shall promptly cooperate with Novartis:

a. in negotiating a case schedule and jointly requesting a prompt scheduling conference date with the Court, with that conference to occur on or before September 28, 2018, or at the Court's earliest convenience thereafter;

b. in negotiating (i) a protective order to govern the exchange of confidential discovery materials; and (ii) an e-discovery protocol for these proceedings; and

c. in producing to Novartis Heritage's Abbreviated New Drug Application No. 207927 according to the Default Standard for Discovery in this District with respect to the production of core technical documents, or such earlier time as agreed to by the parties or ordered by the Court.

Dated: August 9, 2018

GOODWIN PROCTER LLP

/s/ Michael B. Cottler
Michael B. Cottler
The New York Times Building
620 Eighth Avenue
New York, NY 10018
mcottler@goodwinlaw.com
(212) 813-8800

Attorney for Emcure Pharmaceuticals, Ltd. and Heritage Pharmaceuticals Inc.[1]

McCARTER & ENGLISH, LLP

/s/ Daniel M. Silver
Michael P. Kelly (#2295)
Daniel M. Silver (#4758)
Benjamin A. Smyth (#5528)
Renaissance Centre
405 N. King Street, 8th Floor
Wilmington, Delaware 19801
(302) 984-6300
mkelly@mccarter.com
dsilver@mccarter.com
bsmyth@mccarter.com

OF COUNSEL:

Jane M. Love, Ph.D.
Robert Trenchard
Paul E. Torchia
GIBSON, DUNN & CRUTCHER LLP
200 Park Avenue
New York, NY 10166
(212) 351-4000
JLove@gibsondunn.com
RTrenchard@gibsondunn.com
PTorchia@gibsondunn.com

Andrew P. Blythe
GIBSON, DUNN & CRUTCHER LLP
333 South Grand Avenue
Los Angeles, CA 90071
(213) 229-7000
ABlythe@gibsondunn.com

Attorneys for Novartis Pharmaceuticals Corporation

SO ORDERED this _____ day of August, 2018.

_____
Chief United States District Judge

[1] Emcure Pharmaceuticals, Ltd. and Heritage Pharmaceuticals Inc. have not yet retained Delaware counsel.

Attachment 27
(filed under seal)

Attachment 28
(filed under seal)

Attachment 29
(filed under seal)

Attachment 30
(filed under seal)

Attachment 31
(filed under seal)

Attachment 32
(filed under seal)

Attachment 33
(filed under seal)

Attachment 34

Healthcare Provider License Record

Source Information

Information Current Through:	05/06/2019
Database Last Updated:	05/07/2019
Update Frequency:	MONTHLY
Current Date:	06/04/2019
Source:	MISSOURI DIVISION OF PROFESSIONAL REGULATION

Reporting Authority Information

Publication:	DRUG DISTRIBUTOR LICENSE ROSTER
Authority:	MISSOURI DIVISION OF PROFESSIONAL REGULATION
State:	MO

Provider Information:

Name:	EMCURE PHARMACEUTICALS LTD
DBA:	EMCURE PHARMACEUTICALS LTD
Entity Type:	COMPANY
Address:	PLOT NO P-2, ITBT PARK MIDC HINJWADI PINE MAHARASHTRA, 41105
Last Reported:	10/27/2011
Additional Information	PROFESSION=DDR; STATUS=ACTIVE; EXPIRED=NOT EXPIRED; LICENSE PROFESSION=DDR; CLAS_DESCRIPTION=OUT OF STATE WHOLESALE

License Information

License Number:	2008025311
License State:	MO
License First Issue Date:	08/14/2008
License Expiration Date:	10/31/2011
License Status:	ACTIVE;
Provider Type:	SUPPLIERS
Provider Class:	PHARMACY

End of Document

Attachment 35

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home (index.cfm?resetfields=1) | Modify Search (index.cfm?panel=1&sponsor_applicant=EMCURE PHARMACEUTICALS LTD)

Search Results for Applicant: *EMCURE PHARMACEUTICALS LTD*

38 records returned

RX OTC DISCN

CSV | Excel | Print

Display 50 records per page

Search for text in the table:

Mkt. Status	Active Ingredient	Proprietary Name	Appl No	Dosage Form	Route	Strength	TE Code (https://www.fda.gov/Drugs/Developmer
RX	ACARBOSE	ACARBOSE	A202271 (results_product.cfm?Appl_Type=A&Appl_No=202271)	TABLET	ORAL	25MG	AB
RX	ACARBOSE	ACARBOSE	A202271 (results_product.cfm?Appl_Type=A&Appl_No=202271)	TABLET	ORAL	50MG	AB
RX	ACARBOSE	ACARBOSE	A202271 (results_product.cfm?Appl_Type=A&Appl_No=202271)	TABLET	ORAL	100MG	AB
RX	ACETAZOLAMIDE SODIUM	ACETAZOLAMIDE SODIUM	A202693 (results_product.cfm?Appl_Type=A&Appl_No=202693)	INJECTABLE	INJECTION	EQ 500MG BASE/VIAL	AP
RX	ADENOSINE	ADENOSINE	A202313 (results_product.cfm?Appl_Type=A&Appl_No=202313)	SOLUTION	INTRAVENOUS	60MG/20ML (3MG/ML)	AP
RX	ADENOSINE	ADENOSINE	A202313 (results_product.cfm?Appl_Type=A&Appl_No=202313)	SOLUTION	INTRAVENOUS	90MG/30ML (3MG/ML)	AP
RX	AMIKACIN SULFATE	AMIKACIN SULFATE	A204040 (results_product.cfm?Appl_Type=A&Appl_No=204040)	INJECTABLE	INJECTION	EQ 250MG BASE/ML	AP
RX	BENZPHETAMINE HYDROCHLORIDE	BENZPHETAMINE HYDROCHLORIDE	A202061 (results_product.cfm?Appl_Type=A&Appl_No=202061)	TABLET	ORAL	50MG	AA
RX	CARMUSTINE	BICNU	N017422 (results_product.cfm?Appl_Type=N&Appl_No=017422)	INJECTABLE	INJECTION	100MG/VIAL	AP
RX	CIDOFOVIR	CIDOFOVIR	A202501 (results_product.cfm?Appl_Type=A&Appl_No=202501)	INJECTABLE	INJECTION	EQ 75MG BASE/ML	AP
RX	COLISTIMETHATE SODIUM	COLISTIMETHATE SODIUM	A202359 (results_product.cfm?Appl_Type=A&Appl_No=202359)	INJECTABLE	INJECTION	EQ 150MG BASE/VIAL	AP
RX	DOXYCYCLINE HYCLATE	DOXYCYCLINE HYCLATE	A209969 (results_product.cfm?Appl_Type=A&Appl_No=209969)	TABLET	ORAL	EQ 100MG BASE	AB

Mkt. Status	Active Ingredient	Proprietary Name	Appl No	Dosage Form	Route	Strength	TE Code (https://www.fda.gov/Drugs/Developmer

Mkt. Status	Active Ingredient	Proprietary Name	Appl No	Dosage Form	Route	Strength	TE Code (https://www.fda.gov/Drugs/Developmer
RX	ETOMIDATE	ETOMIDATE	A204618 (results_product.cfm?Appl_Type=A&Appl_No=204618)	INJECTABLE	INJECTION	2MG/ML	AP
RX	FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE	FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE	A079025 (results_product.cfm?Appl_Type=A&Appl_No=079025)	TABLET	ORAL	10MG; 12.5MG	AB
RX	FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE	FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE	A079025 (results_product.cfm?Appl_Type=A&Appl_No=079025)	TABLET	ORAL	20MG; 12.5MG	AB
RX	FUROSEMIDE	FUROSEMIDE	A203428 (results_product cfm?Appl_Type=A&Appl_No=203428)	INJECTABLE	INJECTION	10MG/ML	AP
RX	GEMCITABINE HYDROCHLORIDE	GEMCITABINE HYDROCHLORIDE	A202063 (results_product.cfm?Appl_Type=A&Appl_No=202063)	INJECTABLE	INJECTION	EQ 200MG BASE/VIAL	AP
RX	GEMCITABINE HYDROCHLORIDE	GEMCITABINE HYDROCHLORIDE	A202063 (results_product cfm?Appl_Type=A&Appl_No=202063)	INJECTABLE	INJECTION	EQ 1GM BASE/VIAL	AP
RX	IBANDRONATE SODIUM	IBANDRONATE SODIUM	A203987 (results_product.cfm?Appl_Type=A&Appl_No=203987)	INJECTABLE	INTRAVENOUS	EQ 3MG BASE/3ML	AP
RX	IRINOTECAN HYDROCHLORIDE	IRINOTECAN HYDROCHLORIDE	A200771 (results_product cfm?Appl_Type=A&Appl_No=200771)	INJECTABLE	INJECTION	40MG/2ML (20MG/ML)	AP
RX	IRINOTECAN HYDROCHLORIDE	IRINOTECAN HYDROCHLORIDE	A200771 (results_product.cfm?Appl_Type=A&Appl_No=200771)	INJECTABLE	INJECTION	100MG/5ML (20MG/ML)	AP
RX	METOCLOPRAMIDE HYDROCHLORIDE	METOCLOPRAMIDE	A204756 (results_product cfm?Appl_Type=A&Appl_No=204756)	INJECTABLE	INJECTION	EQ 5MG BASE/ML	AP
RX	ONDANSETRON HYDROCHLORIDE	ONDANSETRON HYDROCHLORIDE	A090424 (results_product.cfm?Appl_Type=A&Appl_No=090424)	INJECTABLE	INJECTION	EQ 2MG BASE/ML	AP
RX	ONDANSETRON HYDROCHLORIDE	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE	A078945 (results_product.cfm?Appl_Type=A&Appl_No=078945)	INJECTABLE	INJECTION	EQ 2MG BASE/ML	AP
RX	OXYBUTYNIN CHLORIDE	OXYBUTYNIN CHLORIDE	A211682 (results_product.cfm?Appl_Type=A&Appl_No=211682)	TABLET	ORAL	5MG	AB
RX	PROCHLORPERAZINE EDISYLATE	PROCHLORPERAZINE EDISYLATE	A204147 (results_product.cfm?Appl_Type=A&Appl_No=204147)	INJECTABLE	INJECTION	EQ 5MG BASE/ML	AP
RX	RIFAMPIN	RIFAMPIN	A204101 (results_product.cfm?Appl_Type=A&Appl_No=204101)	INJECTABLE	INJECTION	600MG/VIAL	AP
RX	RIZATRIPTAN BENZOATE	RIZATRIPTAN BENZOATE	A204090 (results_product.cfm?Appl_Type=A&Appl_No=204090)	TABLET	ORAL	EQ 5MG BASE	AB
RX	RIZATRIPTAN BENZOATE	RIZATRIPTAN BENZOATE	A204090 (results_product.cfm?Appl_Type=A&Appl_No=204090)	TABLET	ORAL	EQ 10MG BASE	AB
RX	TRANEXAMIC ACID	TRANEXAMIC ACID	A203521 (results_product.cfm?Appl_Type=A&Appl_No=203521)	INJECTABLE	INJECTION	100MG/ML	AP
RX	VANCOMYCIN HYDROCHLORIDE	VANCOMYCIN HYDROCHLORIDE	A202275 (results_product.cfm?Appl_Type=A&Appl_No=202275)	INJECTABLE	INJECTION	EQ 500MG BASE/VIAL	AP
RX	VANCOMYCIN HYDROCHLORIDE	VANCOMYCIN HYDROCHLORIDE	A202464 (results_product.cfm?Appl_Type=A&Appl_No=202464)	INJECTABLE	INJECTION	EQ 10GM BASE/VIAL	AP
RX	VANCOMYCIN HYDROCHLORIDE	VANCOMYCIN HYDROCHLORIDE	A202275 (results_product.cfm?Appl_Type=A&Appl_No=202275)	INJECTABLE	INJECTION	EQ 1GM BASE/VIAL	AP
RX	VANCOMYCIN HYDROCHLORIDE	VANCOMYCIN HYDROCHLORIDE	A202274 (results_product.cfm?Appl_Type=A&Appl_No=202274)	INJECTABLE	INJECTION	EQ 5GM BASE/VIAL	AP

Mkt. Status	Active Ingredient	Proprietary Name	Appl No	Dosage Form	Route	Strength	TE Code (https://www.fda.gov/Drugs/Developmer

Mkt. Status	Active Ingredient	Proprietary Name	Appl No	Dosage Form	Route	Strength	TE Code (https://www.fda.gov/Drugs/Developmer
RX	ZOLEDRONIC ACID	ZOLEDRONIC ACID	A201783 (results_product.cfm?Appl_Type=A&Appl_No=201783)	INJECTABLE	INTRAVENOUS	EQ 4MG BASE/5ML	AP
RX	ZOLEDRONIC ACID	ZOLEDRONIC ACID	A201801 (results_product.cfm?Appl_Type=A&Appl_No=201801)	INJECTABLE	INTRAVENOUS	EQ 5MG BASE/100ML	AP
DISCN	LEVOFLOXACIN	LEVOFLOXACIN	A202590 (results_product.cfm?Appl_Type=A&Appl_No=202590)	INJECTABLE	INJECTION	EQ 500MG/20ML (EQ 25MG/ML)	
DISCN	LEVOFLOXACIN	LEVOFLOXACIN	A202590 (results_product.cfm?Appl_Type=A&Appl_No=202590)	INJECTABLE	INJECTION	EQ 750MG/30ML (EQ 25MG/ML)	
Mkt. Status	**Active Ingredient**	**Proprietary Name**	**Appl No**	**Dosage Form**	**Route**	**Strength**	**TE Code (https://www.fda.gov/Drugs/Developmer**

howing 1 to 38 of 38 entries

Previous 1 Next

Attachment 36
(filed under seal)

Attachment 37
(filed under seal)

Attachment 38
(filed under seal)

Attachment 39
(filed under seal)